We were delighted to catch up with touchONCOLOGY editorial board member Professor Robin Foà (Sapienza University of Rome, Italy) to discuss his educational session at the 63rd ASH Annual Meeting & Exposition on measurable residual disease in the management of many haematological malignancies. (PART TWO)
Questions
1. Could you give us a brief overview of the concept of measurable residual disease (MRD) and how its use has evolved? 00:17-03:18
2. How is MRD assessed? 03:18-05:55
Speaker Disclosure: Robin Foà has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 63rd ASH Annual Meeting & Exposition
